Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
216 results about "Colon rectal cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method for detecting the methylation of colorectal-cancer-specific methylation marker genes for colorectal cancer diagnosis
ActiveUS20120264640A1Easy to useSugar derivativesMicrobiological testing/measurementColon rectal cancerOncology
The present invention relates to a method for detecting the methylation of colorectal cancer-specific marker genes for colorectal cancer diagnosis, and more particularly to a method of detecting colorectal cancer-specific marker genes, which are methylated specifically in colorectal cancer cells, to provide information for diagnosing colorectal cancer. The use of the inventive method for detecting methylation and the inventive composition, kit and nucleic chip for diagnosing colorectal cancer makes it possible to diagnose colorectal cancer at an early transformation stage, thus enabling the early diagnosis of colorectal cancer. In addition, the inventive method enables colorectal cancer to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.
Owner:GENOMICTREE
Tissue chip used for tumour early stage diagnosis and preparation device
Three kinds of tissues including cancer tissue, precancerosis and corresponding normal tissue are sliced up, dyed, marked, and positioned. Receptor holes are prepared by leading designed lattice array mould paper to paste on surface of wax block of receptor. Wax block with tissue core bar is prepared by using perforating needle and puncture needle for tissue. Common cancer such as lung cancer, nasopharyngeal carcinoma, oesophagus cancer etc. and having integrated clinical data and pathology features are selected. Through in situ hybridization, testing mRNA of relevant gene and expression of protein on tissue chip, consistent result between the invented product and traditional test is validated. In the product, cellular morphology is clear and even, and there is no fallen off tissue point. The invention is applicable to filter cancers, early diagnosis and forecasting prognosis.
Owner:中南大学湘雅医学院肿瘤研究所
Colon cancer marker and application thereof
ActiveCN105132518ARelief of clinical symptomsImprove and restore micro-ecological structureMicrobiological testing/measurementMicroorganism based processesMicroorganismPatient group
The invention discloses a colon cancer marker. The colon cancer marker comprises the microorganisms of rare pediococcocci Subdoligranulum_4_3_54A2FAA and polymorph bacilli Bacteroidses. The invention further discloses a method and device for determining individual states through the colon cancer marker. Compared with healthy individuals and groups, the colon cancer marker is remarkably enriched in patient groups with colon cancer, thereby being capable of serving as a distinguishing mark for healthy groups and patient groups with colon cancer.
Owner:SHANGHAI REALBIO TECH CO LTD
Soap pod saponin extract as well as preparation method and application thereof
InactiveCN101537036ASynergistic effect is obviousProlong survival timeAntineoplastic agentsPlant ingredientsSide effectComplete remission
The invention discloses a soap pod saponin extract, a preparation method thereof and an application for curing lung cancer, liver cancer, stomach cancer, colorectal cancer and leukemia. The soap pod saponin extract uses fructus gleditsiae or fructus gleditsiae sinensis as the raw material and is prepared by the extraction of ethanol, and the separation and the purification of macroporous resin, and the content of total saponin of the extract is more than 60 percent. The saponin extract mainly comprises various pentacyclic triterpene saponin compounds, has obvious lethal effect on the clone of the leukemia progranulocyte HL-60 and the stomach cancer transferring lymphocyte SGC7901 of people, and has remarkably inhibited effect on the tumor of mice S180 and mice having the liver cancer. When capsules prepared by the extract are used for curing 40 examples having liver cancer, lung cancer, stomach cancer and colorectal cancer, the partial remission rate is 45 percent, and the partial remission and stabilization rate is 72.5 percent. When the capsules are used for curing 30 patients who have leukemia, the complete remission rate is 66.7 percent, and the total remission rate is 90 percent which is better than that of a single chemo-treatment group. The extract can obviously lighten the toxic side effect caused by the chemo-treatment.
Owner:SHANDONG ACAD OF CHINESE MEDICINE
Colorectal cancer prognostics
InactiveUS20050048526A1Bioreactor/fermenter combinationsBiological substance pretreatmentsOncologyColorectal cancer
A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.
Owner:WANG YIXIN
Msi-specific frameshift peptides (FSP) for prevention and treatment of cancer
Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention / treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
Owner:UNIVERSITY OF HEIDELBERG
Long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs
InactiveCN108707668APrevent invasionInhibit migrationMicrobiological testing/measurementCancers diagnosisColorectal cancer cell line
The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.
Owner:PEKING UNIV
Composition containing natural minerals and the water extracted therefrom as active ingredients
InactiveCN104039332AGood for healthImprove metabolic activityAntibacterial agentsHeavy metal active ingredientsBULK ACTIVE INGREDIENTFar infrared
The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes, which contains natural minerals and the water extracted therefrom as active ingredients. More particularly, at least one mineral selected from the group consisting of lizardite, antigorite, brucite, magnesite, dolomite, talc, clinochlore, calcite, hornblende, and phologopite, and water which is extracted from the minerals and the quality of which is suitable for the standards of drinking water, contain a significantly large amount of rare earth elements, generate a large amount of far-infrared radiation and anions to enhance and promote health, block various forms of harmful radiation such as water vein waves and electromagnetic waves, stimulate the activity of the metabolism, and have the effects of remarkably inhibiting and reducing blood glucose for type 1 and type 2 diabetes. Therefore, the mineral and the water extracted therefrom can be effectively used in developing: a pharmaceutical composition for the purpose of preventing and treating diabetes, and a healthy food composition having the same purpose; a pharmaceutical composition for the purpose of preventing and treating cancer due to having the remarkable effects of inhibiting tumors from growing or metastasizing in the case of leukemia, colorectal cancer, stomach cancer, lung cancer, and skin cancer, and a healthy food composition having the same purpose; and a pharmaceutical composition for antibacterial purposes due to having highly antibacterial effects against colon bacillus and pseudomonas aeruginosa, as well as a composition to be externally applied to the skin and a cosmetic composition having the same purpose.
Owner:权泰东
Method for establishing colon cancer prognosis prediction model
The invention provides a method for establishing a colon cancer prognosis prediction model. The method comprises the following steps of: detecting the expression levels of SPARCL1 and P53 proteins in colon cancer tissues by immunohistochemistry; grading the tissue expression levels of the SPARCL1 and P53 proteins by a semi-quantitative method; and combining, analyzing and verifying the expression levels of the SPARCL1 and P53 proteins through a support vector machine, and finally establishing a judgment model. Immunohistochemistry detection, marker combination and support vector machine analysis are combined for establishing the colon cancer prediction model. The research shows that the model constructed by using the composition of the SPARCL1 and the P53 as a marker has experiment aid effect of predicting the prognosis of colon cancer patients. The model can be applied in postoperative transfer relapse risk prediction experiments of the colon cancer patients.
Owner:ZHEJIANG UNIV
Chinese medicinal composition with effect of preventing and treating cancers and application of Chinese medicinal composition
ActiveCN102309655AEffective controlAvoid side effectsAntineoplastic agentsPlant ingredientsProstate cancerEsophagus Cancers
The invention discloses a composition with an effect of preventing and treating cancers. The composition is mainly prepared from the following Chinese herbal medicines in percentage by mass: 20 to 85 percent of airpotato yam rhizome and 15 to 80 percent of Chinese angelica. The Chinese medicinal composition has the effect of preventing and treating the cancers, can eliminate the limit that liver injury is easily induced by chemotherapeutic medicinal medicines, is suitable for treating various cancers such as liver cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, ovarian cancer, prostate cancer, esophagus cancer, pancreatic cancer, colon cancer, colorectal cancer, skin cancer, thyroid cancer, cervical carcinoma, leukemia and the like, can be used for preparing anti-cancer medicaments, realizes the application of the airpotato yam rhizome and Chinese angelica compositions to the preparation of medicaments for treating the cancers, develops the application range and the medicinal value of the airpotato yam rhizome and the Chinese angelica and makes creative contribution to the development of traditional Chinese medicine.
Owner:SHANGHAI UNIV OF T C M
Quinoline derivative as well as preparation method and application thereof
ActiveCN104230912ABroad-spectrum anticancer activityStrong inhibitory activityOrganic active ingredientsOrganic chemistryDiseaseQuinoline
The invention discloses a quinoline derivative as shown in the formula (I) in the specification and a salt of the quinoline derivative, wherein in the formula, Z is NH or O; R is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, tertiary butyl, trifluoromethyl, methoxyl or nitryl; n is an integer of 0, 1, 2 or 3. The invention relates to a preparation method and application of the compound as shown in the formula (I) in the specification and the salt of the compound. The compound or the salt has very high inhibition activity for a human lung cancer cell strain A549, a colorectal cancer cell strain HCT-116 and a breast cancer cell strain MCF-7. The compound has a broad-spectrum anti-cancer activity and can be used as a candidate medicine or a lead compound for treating diseases such as tumor and cancer.
Owner:FUJIAN INST OF RES ON THE STRUCTURE OF MATTER CHINESE ACAD OF SCI
Colorectal cancer markers
InactiveUS20160108476A1Accurate and reliable diagnosisDistort confidenceSugar derivativesMicrobiological testing/measurementProstate cancerBiomarker (petroleum)
The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with colorectal cancer compared to subjects without colorectal cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease progression or regression in a patient and the efficacy of therapeutic regimens.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
Kit for genetic detection of colorectal cancer
InactiveCN101608224AMicrobiological testing/measurementFluorescence/phosphorescenceFluorescenceFhit gene
The invention discloses a kit for genetic detection of colorectal cancer. The kit comprises a specific primer pair and a specific probe pair which are used for detecting the mononucleotide polymorphism loci genotype of a 5,10-methylenetetrahydrofolate reductase gene (MTHFR), a glutathione-s-transferase T1 gene (GSTT1), a glutathione-s-transferase M1 gene (GSTM1), a cytochrome P450 2E1 gene (CYP2E1), and a mismatching repair enzyme gene (hMLH1), a fluorescent quantitative PCR general component, a PCR reaction component and the like. The kit can evaluate the genetic risk of individuals suffered from the colorectal cancer by detecting the polymorphism loci genotype of the genes closely related to the genetic risk of the colorectal cancer at the same time.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
11, 20-dicarbonyl Jiyuan rubescensin a and L-amino acid-14-ester trifluoroacetate
ActiveCN110229168ASimple manufacturing methodNo allergiesOrganic chemistryAntineoplastic agentsWilms' tumorLeukemia
Belonging to the field of pharmaceutical compounds, the invention relates to 11, 20-dicarbonyl Jiyuan rubescensin a and L-amino acid-14-ester trifluoroacetate thereof, and a preparation method and usethereof. The preparation method includes: adopting Jiyuan rubescensin a as the raw material and performing oxidation with a Jones reagent, thus obtaining 11, 20-dicarbonyl Jiyuan rubescensin a, the structure of which is shown as the specification; then carrying out 14-position esterification reaction with N-BOC-L-amino acid to obtain N-BOC-L-amino acid-11, 20-dicarbonyl Jiyuan rubescensin a ester(III), then removing BOC protective group in trifluoroacetic acid, and then conducting salt forming to obtain L-amino acid-14-(11, 20-dicarbonyl Jiyuan rubescensin a)ester trifluoroacetate, which hasthe following general formula. The compound has good stability and anti-tumor activity, and provides the basis for screening antitumor drugs against esophageal cancer, gastric cancer, primary liver cancer, pancreatic cancer, cardiac carcinoma, colorectal cancer, bladder cancer, breast cancer, acute myelogenous leukemia and the like.
Owner:ZHENGZHOU UNIV
Physical examination system based on cloud computing
InactiveCN104970883AEasy to operateEasy to upgradeDiagnosticsSurgeryStomach cancerNetwork Access Device
The invention discloses a physical examination system based on cloud computing. The physical examination system comprises a cloud microelement analyzer, a cloud weighing machine, a cloud electrocardioscanner, a cloud pulse monitor, a cloud blood pressure monitor, a cloud blood fat monitor, a cloud blood glucose monitor, a cloud vision monitor, a cloud body temperature monitor, a cloud whole-body thermal imaging monitor, a cloud transcranial Doppler monitor, a cloud bone mineral density and bone age monitor, a cloud carbon 14 breath test part, a cloud human body bio-electricity signal monitor and a cloud stethoscope. The physical examination system comprises a cloud platform, a server platform, a database, a network access device and physical examination instruments. The functions and the number of the physical examination instruments are not limited. The problems that physical examination is difficult and microelements for growth of teenagers are not balanced are solved. Serious diseases without subjective symptoms, for example, the stomach cancer, the colon cancer, the lung cancer, the breast cancer and the uterine cancer, can be found at the germination stage.
Owner:HANGZHOU ZHIER TECH
Methods of treating colorectal cancer
ActiveUS11332529B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesColon rectal cancer
This disclosure provides methods for treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability in a subject comprising administering to the subject an anti-PD-1 antibody. In some embodiments, the method further comprises administering an anti-CTLA-4 antibody. In some embodiments, the colorectal cancer is rectal cancer, colon cancer, or any combination thereof.
Owner:BRISTOL MYERS SQUIBB CO
Diagnostic method for colorectal cancer
The present invention relates to a method of diagnosing patients with colorectal cancer by quantifying the level of one or more proteins, for example immunoglobulins such as IgM, IgG, IgA (total and / or secretory IgA), in a sample of the colorectal mucosa. The invention also relates to methods of monitoring efficacy of colorectal cancer therapy and to kits for diagnosing colorectal cancer by using the method described herein.
Owner:ORIGIN SCI
Method of extracting anti-intestinal cancer active protein from nostoc commune
InactiveCN103059112ALow costHigh activityPeptide preparation methodsAlgae/lichens peptidesSide effectPhosphate
The invention provides a method of extracting anti-intestinal cancer active protein from nostoc commune. The method comprises the following steps: crushing the pure natural nostoc commune, adding PBS (phosphate buffer solution) at low temperature, extracting overnight, then adding pre-cooled acetone to perform the low-temperature treatment to obtain the nostoc commune crude protein extracting solution; adding the ammonium sulfate powder in different saturation in the crude protein extracting solution, fractionally precipitating the protein, wherein the ammonium sulfate precipitate with saturation of 10-60% contains the nostoc commune anti-intestinal cancer active protein; then performing the Q anion column purification on the crude protein, wherein a penetrating solution contains the effective active protein. When the protein is used for treating the colorectal cancer cell for 48 hours, the IC50 value is 35 micrograms, and the protein has no obvious toxic and side effect for the normal cell; and the protein can be used for effectively inhibiting the proliferation of the colorectal cancer cell.
Owner:SHANXI UNIV
Preparation method and application of colon cancer cell strain expressed by stabilized silent PKM2 gene
InactiveCN103451222AEnhanced inhibitory effectMicrobiological testing/measurementTumor/cancer cellsLentivirusLarge Intestine Cancer
The invention provides a preparation method of a colon cancer cell strain expressed by stabilized silent PKM2 gene. The preparation method comprises the steps of constructing of shRNA lentiviral expression vector of human PKM2 gene, packaging and obtaining of lentivirus, DLD1 colon cancer lentivirus infecting, stabilized cell strain puromycin screening and Real-time PCR, Western blot identification. The experimental results show that the shRNA nucleotide sequence can be successfully inserted into the pLKO.1-puro expression vector, and the inhibitory effect on the expression of PKM2 gene is remarkable, endurable and stable. The prepared cell strain can be used as the experimental material for researching the regulating effect of PKM2 in malignant characteristics such as colon cancer cell energy metabolism, cell proliferation, cell migration and inflammation.
Owner:SHANXI UNIV
Colon cancer specific antigenic peptide and colon cancer detection kit
ActiveCN101948525AHigh sensitivity and specificityAnimals/human peptidesVector-based foreign material introductionNegative controlCDNA library
The invention discloses a colon cancer specific antigenic peptide, an expression vector and a preparation method thereof, a colon cancer specific autoantibody enzyme-linked immune detection kit comprising the expression vector and an operation method thereof. The preparation method comprises the following steps of: showing a colon cancer cDNA library onto the surface of a phage by utilizing the phage; screening an expression vector of the colon cancer specific antigenic peptide from the colon cancer cDNA library through affinity screening and serology analysis as a main component; and formingthe detection kit by the main component with a negative control, an elisa plate, a color developing agent, a stop solution, and the like. The expression vector of the colon cancer specific antigenic peptide effectively expresses the colon cancer specific antigenic peptide, is coated on the elisa plate and has the capacity of detecting autoantibodies generated by tumor simulation in the blood serum of a colon cancer patient so as to achieve the purposes of early detecting and screening colon cancer patients.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Full-nutrition formula food for colorectal cancer
InactiveCN104323240AImprove intestinal adhesionPlay a role in colonizationVitamin food ingredientsAcidic food ingredientsFormularyColon rectal cancer
Owner:胡安然
Anti-tumor medicament based on alpha ketoglutaric acid and derivatives thereof
The invention belongs to the technical field of biomedicine and relates to an anti-tumor medicament based on alpha ketoglutaric acid and derivatives thereof. The derivatives comprise various ester derivatives, amide derivatives and ether derivatives; and the alpha ketoglutaric acid comprises chemical analogues and derivatives thereof. The results of in-vitro experiments indicate that the mutation of isocitrate dehydrogenase in gliomas results in the loss of enzyme activities, the alpha ketoglutaric acid capable of growing in cells is obvious reduced, the levels of anaerobic inductor factors capable of inducing tumors and promoting the growth of the tumors are obviously improved, and the phenomenon can be reversed by exogenously replenishing absorbable alpha ketoglutaric acid. Therefore, an absorbable alpha ketoglutaric acid compound can be used for treating the gliomas, pancreatic cancers, breast cancers, liver cancers, lung cancers, gastric cancers, colorectal cancers, colon cancer and melanomas.
Owner:FUDAN UNIV
Kit for detecting bacteria DNAs in faeces and application thereof in colorectal cancer diagnosis
The invention discloses a kit for detecting bacteria DNAs in faeces and the application thereof in colorectal cancer screening, diagnosis or auxiliary diagnosis. Bacteria DNAs in faeces are extracted and sequenced to obtain the species and abundance of bacteria, and colorectal cancer diagnosis is conducted based on the abundance of various bacteria. Compared with existing noninvasive colorectal cancer screen methods which have already been used clinically or for patent application, the kit has the advantages that the kit is completely noninvasive, colorectal cancer can be predicted and diagnosed more accurately, and the ROC area under the curve can be as high as 0.994.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention / treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
Owner:UNIVERSITY OF HEIDELBERG
New functions and applications of trametes lactinea(Berk.)Pat. or extractives and trametenloic acid B
The invention relates to new functions and applications of trametes lactinea(Berk.)Pat. or extractives and trametenloic acid B. The substance trametes lactinea(Berk.)Pat has the functions of digestive gastric ulcer resistance, and nonulcerative-indigestion resistance through increasing of gastric motility. The trametes lactinea(Berk.)Pat. or the extractives and the trametenloic acid B have certain inbibitional effects on cell proliferation of gastric cancer cells, esophagus cancer cells Eca-109 and colorectal cancer cells LOVO, and has a wide range of research value and mass production and edible value in dugs for digestive system and gastric cancer resisting and the like.
Owner:CHINA THREE GORGES UNIV
Human colon carcinoma cell line DXH-1 and application thereof
ActiveCN105296430AStrong tumorigenic abilityMicrobiological testing/measurementUnknown materialsTransfer cellSigmoid colon carcinoma
The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.
Owner:ZHEJIANG UNIV
Method of examining colon cancer and colon adenoma
InactiveUS20070196874A1Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsNon cancerIsozyme
The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.
Owner:JAPAN SCI & TECH CORP +2
Method for detecting the methylation of colorectal-cancer-specific methylation marker genes for colorectal cancer diagnosis
ActiveUS9745622B2Easy to useSugar derivativesMicrobiological testing/measurementColon rectal cancerOncology
Owner:GENOMICTREE
Analysis/diagnosis method utilizing RNA modification
PendingCN112004942ABioreactor/fermenter combinationsBiological substance pretreatmentsDiseaseRNA modification
The present application provides a novel method for analyzing a biological condition or a medical condition. It is now found that information about the modification of RNA can be used for the analysisof a biological condition or a medical condition. On the basis of this finding, the present invention provides a novel method for analyzing a biological condition or a medical condition. According tothe present invention, it becomes possible to analyze various biological conditions or medical conditions including diseases, and it also becomes possible to satisfactorily predict cancer (e.g., pancreatic cancer, colorectal cancer, stomach cancer) in an early stage.
Owner:OSAKA UNIV
Optical imaging of colorectal cancer
InactiveUS20060292078A1High amountUltrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsIn patientColorectal cancer
The invention provides contrast agents for optical imaging of colorectal cancer (CRC) in patients. The contrast agents may be used in diagnosis of CRC, for follow up of progress in disease development, and for follow up of treatment of CRC. Further, the invention provides methods for optical imaging of CRC in patients.
Owner:KLAVENESS JO +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com